Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1985-8-16
|
pubmed:abstractText |
Eighty-four previously untreated patients (69 males, 15 females) with squamous carcinoma of the tongue (30 patients), floor of the mouth (30), cheek (16), and retromolar region (8) were treated using a protocol comprising cryosurgery + chemotherapy, followed by external 60Co radiotherapy. The follow-up period was at least 6 months (median, 50 months). Cryosurgery (1-2 sessions in 49 T1-2 cases; 2-4 in 35 T3-4 cases) was accompanied by a CMF (cyclophosphamide, methotrexate, 5-fluorouracil) schedule (T1-2, two courses; T3-4, three courses). Radiotherapy was given 15 to 20 days after combined cryochemotherapy (T1, 50 Gy on tumor and lymph nodes; T2-3-4, same with an extra dose of 10 to 15 Gy on the primary lesion). Complete remission was reached 4 months after treatment in 76 of 84 patients (90.5%). Survival with no evidence of disease (NED) in the 57 patients (27 T1-2, 30 T3-4) with a follow-up of more than 3 years was 59.6% for the series as a whole, 70.3% for T1-2, and 50.0% for T3-4; 78.2% for the tongue, 52.6% for the floor, 66.6% for the cheek, and 0% for the retromolar region. The picture was much the same after 5 years. Actuarial survival at 6 years was 66% in the series as a whole, 75.5% in T1-2, and 57.5% in T3-4 (tongue 86.9%, floor 56.1%, cheek 68.4%, and retromolar region 0%). It is believed that the results obtained in tumors of the tongue, floor and cheek, coupled with the conservative aspects of the protocol, make it a suitable subject for a controlled trial.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
424-31
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3839159-Adult,
pubmed-meshheading:3839159-Aged,
pubmed-meshheading:3839159-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3839159-Carcinoma, Squamous Cell,
pubmed-meshheading:3839159-Cobalt Radioisotopes,
pubmed-meshheading:3839159-Combined Modality Therapy,
pubmed-meshheading:3839159-Cryosurgery,
pubmed-meshheading:3839159-Cyclophosphamide,
pubmed-meshheading:3839159-Female,
pubmed-meshheading:3839159-Fluorouracil,
pubmed-meshheading:3839159-Humans,
pubmed-meshheading:3839159-Lymphatic Metastasis,
pubmed-meshheading:3839159-Male,
pubmed-meshheading:3839159-Methotrexate,
pubmed-meshheading:3839159-Middle Aged,
pubmed-meshheading:3839159-Mouth Neoplasms,
pubmed-meshheading:3839159-Neck Dissection,
pubmed-meshheading:3839159-Neoplasm Recurrence, Local,
pubmed-meshheading:3839159-Neoplasm Staging,
pubmed-meshheading:3839159-Prognosis,
pubmed-meshheading:3839159-Radioisotope Teletherapy
|
pubmed:year |
1985
|
pubmed:articleTitle |
Combined cryosurgical, chemotherapeutic, and radiotherapeutic management of T1-4N0M0 oral cavity cancers.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|